

Date	Presenter	Title	Journal	Year	Vol	Page
2021/4/6	藤岡	Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes	J Clin Oncol	2021	39(14)	1584-1594
	宮崎	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms	Cell Stem Cell	2021	28(3)	514-523
2020/4/13	山田	Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers	N Engl J Med	2021	384(10)	924-935
	佐藤	Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria	N Engl J Med	2021	384(11)	1028-1037
2020/4/20	クリクラ	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial	Blood Adv	2021	5(4)	984-993
	長井	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large	Nat Med	2020	26(12)	1878-1887
2020/4/27	渡辺	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelody	J Clin Oncol	2021	39(13)	1426-1436
	澤山	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial	J Clin Oncol	2021		JCO2003175
2020/5/11	古本	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with prev	Lancet Oncol	2020	21(3)	387-397
	加藤	Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody	Cell	2020	180(5)	878-894
2020/5/18	山田	日本リンパ網内系学会予行				
	長井	臨床研究説明「幹細胞輸注関連有害事象と移植合併症の相関の前向き観察研究」福島県立医科大学				
2020/5/25	クリクラ	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma	J Clin Oncol	2021		JCO2100108
	今泉	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?	J Clin Oncol	2021	39(15)	1641-1649
2020/6/1	勝岡	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery	Blood Adv	2020	4(15)	3586-3593
	安東	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation	Cancer Cell	2021	39(3)	380-393
2020/6/8	西村	Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-C	Blood Adv	2021	5(8)	2229-2236
	宮崎	Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.	N Engl J Med	2020	383(27)	2628-2638
2020/6/15	坂本	ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease	J Clin Oncol	2021	39(17)	1888-1898
	佐藤	Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)	J Clin Oncol	2021	39(14)	1575-1583
2020/6/22	クリクラ	Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination	N Engl J Med	2021	384(22)	2124-2130
	長井	Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia	Blood Adv	2021	5(9)	2350-2361
2020/6/29	藤岡	Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia	Nature	2021	593(7860)	597-601
	澤山	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison	Blood Adv	2020	4(24)	6157-6168